Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Single arm study (n=30) reports ezetimibe (an HCV entry inhibitor) with glecaprevir-pibrentasvir (1 dose before and for 7 days post-transplant) resulted in all 30 recipients having undetectable HCV RNA 12 weeks post-transplant and at last follow-up (median 36 weeks).

SPS commentary:

Authors of a related commentary state the development of oral direct-acting antiviral (DAA) therapy for HCV has revolutionised HCV management, and has made possible solid organ transplantation from HCV-positive donors to HCV-negative recipients. However, the optimal timing and duration of DAAs remain unknown and access to DAAs immediately after transplant might be limited and costly.


Lancet Gastroenterology and Hepatology

Resource links: